#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Currently , we expect foods to satisfy hunger while delivering nutrients essential for humans , but their task is also the prevention of diet-related diseases .
2-1	16-25	Currently	_	_	_	_
2-2	26-27	,	_	_	_	_
2-3	28-30	we	person	acc	ana	10-2
2-4	31-37	expect	_	_	_	_
2-5	38-43	foods	substance	new	coref	3-1[11_0]
2-6	44-46	to	_	_	_	_
2-7	47-54	satisfy	_	_	_	_
2-8	55-61	hunger	abstract	new	_	_
2-9	62-67	while	_	_	_	_
2-10	68-78	delivering	_	_	_	_
2-11	79-88	nutrients	substance[5]	new[5]	coref	4-17[19_5]
2-12	89-98	essential	substance[5]	new[5]	_	_
2-13	99-102	for	_	_	_	_
2-14	103-109	humans	person	new	ana	2-17
2-15	110-111	,	_	_	_	_
2-16	112-115	but	_	_	_	_
2-17	116-121	their	person|abstract[8]	giv|new[8]	coref	2-21[9_8]
2-18	122-126	task	abstract[8]	new[8]	_	_
2-19	127-129	is	_	_	_	_
2-20	130-134	also	_	_	_	_
2-21	135-138	the	abstract[9]	giv[9]	_	_
2-22	139-149	prevention	abstract[9]	giv[9]	_	_
2-23	150-152	of	abstract[9]	giv[9]	_	_
2-24	153-165	diet-related	abstract[9]|abstract[10]	giv[9]|new[10]	_	_
2-25	166-174	diseases	abstract[9]|abstract[10]	giv[9]|new[10]	_	_
2-26	175-176	.	_	_	_	_

#Text=Functional foods play a significant role in this case .
3-1	177-187	Functional	substance[11]	giv[11]	ana	4-3[0_11]
3-2	188-193	foods	substance[11]	giv[11]	_	_
3-3	194-198	play	_	_	_	_
3-4	199-200	a	abstract[12]	new[12]	_	_
3-5	201-212	significant	abstract[12]	new[12]	_	_
3-6	213-217	role	abstract[12]	new[12]	_	_
3-7	218-220	in	abstract[12]	new[12]	_	_
3-8	221-225	this	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-9	226-230	case	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-10	231-232	.	_	_	_	_

#Text=Due to their beneficial physiological effects , including antioxidant , anticancer , and anti-inflammatory properties , nutrients from marine animals , as well as bioactive components have great potential as ingredients in functional foods .
4-1	233-236	Due	_	_	_	_
4-2	237-239	to	_	_	_	_
4-3	240-245	their	substance|abstract[15]	giv|new[15]	coref|coref	4-33[23_0]|22-22[155_15]
4-4	246-256	beneficial	abstract[15]	new[15]	_	_
4-5	257-270	physiological	abstract[15]	new[15]	_	_
4-6	271-278	effects	abstract[15]	new[15]	_	_
4-7	279-280	,	abstract[15]	new[15]	_	_
4-8	281-290	including	abstract[15]	new[15]	_	_
4-9	291-302	antioxidant	abstract[15]|substance	new[15]|new	coref	13-1
4-10	303-304	,	abstract[15]	new[15]	_	_
4-11	305-315	anticancer	abstract[15]|substance	new[15]|new	_	_
4-12	316-317	,	abstract[15]	new[15]	_	_
4-13	318-321	and	abstract[15]	new[15]	_	_
4-14	322-339	anti-inflammatory	abstract[15]|abstract[18]	new[15]|new[18]	coref	14-16[89_18]
4-15	340-350	properties	abstract[15]|abstract[18]	new[15]|new[18]	_	_
4-16	351-352	,	abstract[15]	new[15]	_	_
4-17	353-362	nutrients	abstract[15]|substance[19]	new[15]|giv[19]	coref	22-13[0_19]
4-18	363-367	from	abstract[15]|substance[19]	new[15]|giv[19]	_	_
4-19	368-374	marine	abstract[15]|substance[19]|animal[20]	new[15]|giv[19]|new[20]	_	_
4-20	375-382	animals	abstract[15]|substance[19]|animal[20]	new[15]|giv[19]|new[20]	_	_
4-21	383-384	,	abstract[15]	new[15]	_	_
4-22	385-387	as	abstract[15]	new[15]	_	_
4-23	388-392	well	abstract[15]	new[15]	_	_
4-24	393-395	as	abstract[15]	new[15]	_	_
4-25	396-405	bioactive	abstract[15]|substance[21]	new[15]|new[21]	_	_
4-26	406-416	components	abstract[15]|substance[21]	new[15]|new[21]	_	_
4-27	417-421	have	_	_	_	_
4-28	422-427	great	abstract[22]	new[22]	_	_
4-29	428-437	potential	abstract[22]	new[22]	_	_
4-30	438-440	as	abstract[22]	new[22]	_	_
4-31	441-452	ingredients	abstract[22]	new[22]	_	_
4-32	453-455	in	abstract[22]	new[22]	_	_
4-33	456-466	functional	abstract[22]|substance[23]	new[22]|giv[23]	_	_
4-34	467-472	foods	abstract[22]|substance[23]	new[22]|giv[23]	_	_
4-35	473-474	.	_	_	_	_

#Text=After filleting , fish processing waste comprises 75 % of the overall fish weight .
5-1	475-480	After	_	_	_	_
5-2	481-490	filleting	abstract	new	_	_
5-3	491-492	,	_	_	_	_
5-4	493-497	fish	animal|abstract[27]	new|new[27]	coref|coref	5-13|6-5[32_27]
5-5	498-508	processing	abstract|abstract[27]	new|new[27]	coref	7-6[37_0]
5-6	509-514	waste	abstract[27]	new[27]	_	_
5-7	515-524	comprises	_	_	_	_
5-8	525-527	75	quantity[28]	new[28]	_	_
5-9	528-529	%	quantity[28]	new[28]	_	_
5-10	530-532	of	quantity[28]	new[28]	_	_
5-11	533-536	the	quantity[28]|abstract[30]	new[28]|new[30]	_	_
5-12	537-544	overall	quantity[28]|abstract[30]	new[28]|new[30]	_	_
5-13	545-549	fish	quantity[28]|animal|abstract[30]	new[28]|giv|new[30]	coref	7-9
5-14	550-556	weight	quantity[28]|abstract[30]	new[28]|new[30]	_	_
5-15	557-558	.	_	_	_	_

#Text=Approximately 30 % of the waste is in the form of bones and skins .
6-1	559-572	Approximately	quantity[31]	new[31]	ana	8-1[0_31]
6-2	573-575	30	quantity[31]	new[31]	_	_
6-3	576-577	%	quantity[31]	new[31]	_	_
6-4	578-580	of	quantity[31]	new[31]	_	_
6-5	581-584	the	quantity[31]|abstract[32]	new[31]|giv[32]	_	_
6-6	585-590	waste	quantity[31]|abstract[32]	new[31]|giv[32]	_	_
6-7	591-593	is	_	_	_	_
6-8	594-596	in	_	_	_	_
6-9	597-600	the	abstract[33]	new[33]	_	_
6-10	601-605	form	abstract[33]	new[33]	_	_
6-11	606-608	of	abstract[33]	new[33]	_	_
6-12	609-614	bones	abstract[33]|object	new[33]|new	_	_
6-13	615-618	and	abstract[33]	new[33]	_	_
6-14	619-624	skins	abstract[33]|object	new[33]|new	coref	7-9[39_0]
6-15	625-626	.	_	_	_	_

#Text=Gelatine can be derived from the processing of fish skins , solving the problem of waste disposal while producing a value-added product .
7-1	627-635	Gelatine	substance	new	coref	10-14
7-2	636-639	can	_	_	_	_
7-3	640-642	be	_	_	_	_
7-4	643-650	derived	_	_	_	_
7-5	651-655	from	_	_	_	_
7-6	656-659	the	abstract[37]	giv[37]	coref	12-16[78_37]
7-7	660-670	processing	abstract[37]	giv[37]	_	_
7-8	671-673	of	abstract[37]	giv[37]	_	_
7-9	674-678	fish	abstract[37]|animal|object[39]	giv[37]|giv|giv[39]	coref	14-12
7-10	679-684	skins	abstract[37]|object[39]	giv[37]|giv[39]	_	_
7-11	685-686	,	_	_	_	_
7-12	687-694	solving	_	_	_	_
7-13	695-698	the	abstract[40]	new[40]	_	_
7-14	699-706	problem	abstract[40]	new[40]	_	_
7-15	707-709	of	abstract[40]	new[40]	_	_
7-16	710-715	waste	abstract[40]|abstract[41]	new[40]|new[41]	_	_
7-17	716-724	disposal	abstract[40]|abstract[41]	new[40]|new[41]	_	_
7-18	725-730	while	_	_	_	_
7-19	731-740	producing	_	_	_	_
7-20	741-742	a	object[42]	new[42]	coref	22-37[159_42]
7-21	743-754	value-added	object[42]	new[42]	_	_
7-22	755-762	product	object[42]	new[42]	_	_
7-23	763-764	.	_	_	_	_

#Text=Its fast growth rate , as well as good fodder usage cause carp ( Cyprinus carpio ) to be one of the most commonly-bred species in eastern Europe , as well as in Poland .
8-1	765-768	Its	quantity|abstract[45]	giv|new[45]	_	_
8-2	769-773	fast	abstract[45]	new[45]	_	_
8-3	774-780	growth	abstract|abstract[45]	new|new[45]	_	_
8-4	781-785	rate	abstract[45]	new[45]	_	_
8-5	786-787	,	_	_	_	_
8-6	788-790	as	_	_	_	_
8-7	791-795	well	_	_	_	_
8-8	796-798	as	_	_	_	_
8-9	799-803	good	abstract[48]	new[48]	appos	8-15[49_48]
8-10	804-810	fodder	object|abstract[48]	new|new[48]	_	_
8-11	811-816	usage	abstract|abstract[48]	new|new[48]	coref	16-1[98_0]
8-12	817-822	cause	abstract[48]	new[48]	_	_
8-13	823-827	carp	abstract[48]	new[48]	_	_
8-14	828-829	(	_	_	_	_
8-15	830-838	Cyprinus	abstract[49]	giv[49]	coref	9-4[0_49]
8-16	839-845	carpio	abstract[49]	giv[49]	_	_
8-17	846-847	)	_	_	_	_
8-18	848-850	to	_	_	_	_
8-19	851-853	be	_	_	_	_
8-20	854-857	one	abstract[50]	new[50]	_	_
8-21	858-860	of	abstract[50]	new[50]	_	_
8-22	861-864	the	abstract[50]|abstract[51]	new[50]|new[51]	coref	27-6[183_51]
8-23	865-869	most	abstract[50]|abstract[51]	new[50]|new[51]	_	_
8-24	870-883	commonly-bred	abstract[50]|abstract[51]	new[50]|new[51]	_	_
8-25	884-891	species	abstract[50]|abstract[51]	new[50]|new[51]	_	_
8-26	892-894	in	abstract[50]|abstract[51]	new[50]|new[51]	_	_
8-27	895-902	eastern	abstract[50]|abstract[51]|place[52]	new[50]|new[51]|new[52]	_	_
8-28	903-909	Europe	abstract[50]|abstract[51]|place[52]	new[50]|new[51]|new[52]	_	_
8-29	910-911	,	_	_	_	_
8-30	912-914	as	_	_	_	_
8-31	915-919	well	_	_	_	_
8-32	920-922	as	_	_	_	_
8-33	923-925	in	_	_	_	_
8-34	926-932	Poland	place	new	_	_
8-35	933-934	.	_	_	_	_

#Text=The annual European carp production totals approximately 4,328,083 tons .
9-1	935-938	The	abstract[55]	new[55]	_	_
9-2	939-945	annual	abstract[55]	new[55]	_	_
9-3	946-954	European	abstract[55]	new[55]	_	_
9-4	955-959	carp	abstract|abstract[55]	giv|new[55]	coref	10-12
9-5	960-970	production	abstract[55]	new[55]	_	_
9-6	971-977	totals	_	_	_	_
9-7	978-991	approximately	quantity[56]	new[56]	_	_
9-8	992-1001	4,328,083	quantity[56]	new[56]	_	_
9-9	1002-1006	tons	quantity[56]	new[56]	_	_
9-10	1007-1008	.	_	_	_	_

#Text=In our previous research , we demonstrated that protein hydrolysates from carp skin gelatine hydrolysate ( CSGH ) can be potential bioactive peptide sources .
10-1	1009-1011	In	_	_	_	_
10-2	1012-1015	our	person|abstract[58]	giv|new[58]	ana|coref	10-6|23-2[160_58]
10-3	1016-1024	previous	abstract[58]	new[58]	_	_
10-4	1025-1033	research	abstract[58]	new[58]	_	_
10-5	1034-1035	,	_	_	_	_
10-6	1036-1038	we	person	giv	_	_
10-7	1039-1051	demonstrated	_	_	_	_
10-8	1052-1056	that	_	_	_	_
10-9	1057-1064	protein	substance|abstract[61]	new|new[61]	coref|coref	10-21[68_61]|14-13
10-10	1065-1077	hydrolysates	abstract[61]	new[61]	_	_
10-11	1078-1082	from	abstract[61]	new[61]	_	_
10-12	1083-1087	carp	abstract[61]|abstract|object[65]	new[61]|giv|new[65]	appos	10-17[0_65]
10-13	1088-1092	skin	abstract[61]|object|object[65]	new[61]|new|new[65]	_	_
10-14	1093-1101	gelatine	abstract[61]|abstract|object[65]	new[61]|giv|new[65]	_	_
10-15	1102-1113	hydrolysate	abstract[61]|object[65]	new[61]|new[65]	_	_
10-16	1114-1115	(	_	_	_	_
10-17	1116-1120	CSGH	object	giv	_	_
10-18	1121-1122	)	_	_	_	_
10-19	1123-1126	can	_	_	_	_
10-20	1127-1129	be	_	_	_	_
10-21	1130-1139	potential	abstract[68]	giv[68]	coref	14-12[87_68]
10-22	1140-1149	bioactive	abstract[68]	giv[68]	_	_
10-23	1150-1157	peptide	place|abstract[68]	new|giv[68]	coref	15-8
10-24	1158-1165	sources	abstract[68]	giv[68]	_	_
10-25	1166-1167	.	_	_	_	_

#Text=Bioactive peptides consisting of 2 – 20 residues of amino acids are inactive within the sequences of parent proteins .
11-1	1168-1177	Bioactive	object[69]	new[69]	coref	13-1[80_69]
11-2	1178-1186	peptides	object[69]	new[69]	_	_
11-3	1187-1197	consisting	_	_	_	_
11-4	1198-1200	of	_	_	_	_
11-5	1201-1202	2	time[70]	new[70]	_	_
11-6	1203-1204	–	time[70]	new[70]	_	_
11-7	1205-1207	20	time[70]	new[70]	_	_
11-8	1208-1216	residues	time[70]	new[70]	_	_
11-9	1217-1219	of	time[70]	new[70]	_	_
11-10	1220-1225	amino	time[70]|substance[71]	new[70]|new[71]	ana	12-1[0_71]
11-11	1226-1231	acids	time[70]|substance[71]	new[70]|new[71]	_	_
11-12	1232-1235	are	_	_	_	_
11-13	1236-1244	inactive	_	_	_	_
11-14	1245-1251	within	_	_	_	_
11-15	1252-1255	the	abstract[72]	new[72]	_	_
11-16	1256-1265	sequences	abstract[72]	new[72]	_	_
11-17	1266-1268	of	abstract[72]	new[72]	_	_
11-18	1269-1275	parent	abstract[72]|substance[73]	new[72]|new[73]	coref	20-10[0_73]
11-19	1276-1284	proteins	abstract[72]|substance[73]	new[72]|new[73]	_	_
11-20	1285-1286	.	_	_	_	_

#Text=They can be released via enzymatic hydrolysis either at the time of digestion or during food processing .
12-1	1287-1291	They	substance	giv	_	_
12-2	1292-1295	can	_	_	_	_
12-3	1296-1298	be	_	_	_	_
12-4	1299-1307	released	_	_	_	_
12-5	1308-1311	via	_	_	_	_
12-6	1312-1321	enzymatic	substance[75]	new[75]	_	_
12-7	1322-1332	hydrolysis	substance[75]	new[75]	_	_
12-8	1333-1339	either	_	_	_	_
12-9	1340-1342	at	_	_	_	_
12-10	1343-1346	the	_	_	_	_
12-11	1347-1351	time	_	_	_	_
12-12	1352-1354	of	_	_	_	_
12-13	1355-1364	digestion	substance	new	_	_
12-14	1365-1367	or	_	_	_	_
12-15	1368-1374	during	_	_	_	_
12-16	1375-1379	food	substance|abstract[78]	new|giv[78]	coref	14-7
12-17	1380-1390	processing	abstract[78]	giv[78]	_	_
12-18	1391-1392	.	_	_	_	_

#Text=Antioxidant peptides are among the most frequently-studied bioactive peptides .
13-1	1393-1404	Antioxidant	person|object[80]	giv|giv[80]	coref|coref	13-5[81_80]|14-16
13-2	1405-1413	peptides	object[80]	giv[80]	_	_
13-3	1414-1417	are	_	_	_	_
13-4	1418-1423	among	_	_	_	_
13-5	1424-1427	the	object[81]	giv[81]	coref	26-1[177_81]
13-6	1428-1432	most	object[81]	giv[81]	_	_
13-7	1433-1451	frequently-studied	object[81]	giv[81]	_	_
13-8	1452-1461	bioactive	object[81]	giv[81]	_	_
13-9	1462-1470	peptides	object[81]	giv[81]	_	_
13-10	1471-1472	.	_	_	_	_

#Text=In particular , in the health food and pharmaceutical industry , fish protein hydrolysates with antioxidant properties have become a highly interesting and discussed subject .
14-1	1473-1475	In	_	_	_	_
14-2	1476-1486	particular	_	_	_	_
14-3	1487-1488	,	_	_	_	_
14-4	1489-1491	in	_	_	_	_
14-5	1492-1495	the	abstract[84]	new[84]	coref	33-42[245_84]
14-6	1496-1502	health	abstract|abstract[84]	new|new[84]	_	_
14-7	1503-1507	food	substance|abstract[84]	giv|new[84]	coref	21-19[147_0]
14-8	1508-1511	and	abstract[84]	new[84]	_	_
14-9	1512-1526	pharmaceutical	abstract[84]	new[84]	_	_
14-10	1527-1535	industry	abstract[84]	new[84]	_	_
14-11	1536-1537	,	_	_	_	_
14-12	1538-1542	fish	animal|abstract[87]	giv|giv[87]	coref	27-10[185_87]
14-13	1543-1550	protein	substance|abstract[87]	giv|giv[87]	coref	23-10
14-14	1551-1563	hydrolysates	abstract[87]	giv[87]	_	_
14-15	1564-1568	with	abstract[87]	giv[87]	_	_
14-16	1569-1580	antioxidant	abstract[87]|person|abstract[89]	giv[87]|giv|giv[89]	coref	25-10[174_89]
14-17	1581-1591	properties	abstract[87]|abstract[89]	giv[87]|giv[89]	_	_
14-18	1592-1596	have	_	_	_	_
14-19	1597-1603	become	_	_	_	_
14-20	1604-1605	a	_	_	_	_
14-21	1606-1612	highly	_	_	_	_
14-22	1613-1624	interesting	_	_	_	_
14-23	1625-1628	and	_	_	_	_
14-24	1629-1638	discussed	_	_	_	_
14-25	1639-1646	subject	_	_	_	_
14-26	1647-1648	.	_	_	_	_

#Text=There can be a reduction in bioactive peptide activity due to susceptibility to proteolytic degradation or undesirable interactions with other compounds .
15-1	1649-1654	There	_	_	_	_
15-2	1655-1658	can	_	_	_	_
15-3	1659-1661	be	_	_	_	_
15-4	1662-1663	a	abstract[90]	new[90]	_	_
15-5	1664-1673	reduction	abstract[90]	new[90]	_	_
15-6	1674-1676	in	abstract[90]	new[90]	_	_
15-7	1677-1686	bioactive	abstract[90]|abstract[92]	new[90]|new[92]	_	_
15-8	1687-1694	peptide	abstract[90]|substance|abstract[92]	new[90]|giv|new[92]	_	_
15-9	1695-1703	activity	abstract[90]|abstract[92]	new[90]|new[92]	_	_
15-10	1704-1707	due	_	_	_	_
15-11	1708-1710	to	_	_	_	_
15-12	1711-1725	susceptibility	abstract[93]	new[93]	_	_
15-13	1726-1728	to	abstract[93]	new[93]	_	_
15-14	1729-1740	proteolytic	abstract[93]|abstract[94]	new[93]|new[94]	coref	18-17[0_94]
15-15	1741-1752	degradation	abstract[93]|abstract[94]	new[93]|new[94]	_	_
15-16	1753-1755	or	abstract[93]	new[93]	_	_
15-17	1756-1767	undesirable	abstract[93]|abstract[95]	new[93]|new[95]	coref	35-1[253_95]
15-18	1768-1780	interactions	abstract[93]|abstract[95]	new[93]|new[95]	_	_
15-19	1781-1785	with	abstract[93]|abstract[95]	new[93]|new[95]	_	_
15-20	1786-1791	other	abstract[93]|abstract[95]|substance[96]	new[93]|new[95]|new[96]	coref	25-13[175_96]
15-21	1792-1801	compounds	abstract[93]|abstract[95]|substance[96]	new[93]|new[95]|new[96]	_	_
15-22	1802-1803	.	_	_	_	_

#Text=Encapsulation usage is a highly significant factor in the protection of these biomolecules , consequently providing greater therapeutic efficacy .
16-1	1804-1817	Encapsulation	abstract|abstract[98]	new|giv[98]	coref|coref	16-4[99_98]|17-1
16-2	1818-1823	usage	abstract[98]	giv[98]	_	_
16-3	1824-1826	is	_	_	_	_
16-4	1827-1828	a	abstract[99]	giv[99]	_	_
16-5	1829-1835	highly	abstract[99]	giv[99]	_	_
16-6	1836-1847	significant	abstract[99]	giv[99]	_	_
16-7	1848-1854	factor	abstract[99]	giv[99]	_	_
16-8	1855-1857	in	abstract[99]	giv[99]	_	_
16-9	1858-1861	the	abstract[99]|abstract[100]	giv[99]|new[100]	_	_
16-10	1862-1872	protection	abstract[99]|abstract[100]	giv[99]|new[100]	_	_
16-11	1873-1875	of	abstract[99]|abstract[100]	giv[99]|new[100]	_	_
16-12	1876-1881	these	abstract[99]|abstract[100]|substance[101]	giv[99]|new[100]|new[101]	_	_
16-13	1882-1894	biomolecules	abstract[99]|abstract[100]|substance[101]	giv[99]|new[100]|new[101]	_	_
16-14	1895-1896	,	_	_	_	_
16-15	1897-1909	consequently	_	_	_	_
16-16	1910-1919	providing	_	_	_	_
16-17	1920-1927	greater	abstract[102]	new[102]	_	_
16-18	1928-1939	therapeutic	abstract[102]	new[102]	_	_
16-19	1940-1948	efficacy	abstract[102]	new[102]	_	_
16-20	1949-1950	.	_	_	_	_

#Text=Encapsulation may also permit the development of the delivery system through the improvement of stability , causing an increase in residence time regarding circulation , while at the same time causing a significant decrease in toxicity .
17-1	1951-1964	Encapsulation	abstract	giv	_	_
17-2	1965-1968	may	_	_	_	_
17-3	1969-1973	also	_	_	_	_
17-4	1974-1980	permit	_	_	_	_
17-5	1981-1984	the	abstract[104]	new[104]	_	_
17-6	1985-1996	development	abstract[104]	new[104]	_	_
17-7	1997-1999	of	abstract[104]	new[104]	_	_
17-8	2000-2003	the	abstract[104]|abstract[106]	new[104]|new[106]	_	_
17-9	2004-2012	delivery	abstract[104]|abstract|abstract[106]	new[104]|new|new[106]	coref	19-5
17-10	2013-2019	system	abstract[104]|abstract[106]	new[104]|new[106]	_	_
17-11	2020-2027	through	abstract[104]|abstract[106]	new[104]|new[106]	_	_
17-12	2028-2031	the	abstract[104]|abstract[106]|abstract[107]	new[104]|new[106]|new[107]	_	_
17-13	2032-2043	improvement	abstract[104]|abstract[106]|abstract[107]	new[104]|new[106]|new[107]	_	_
17-14	2044-2046	of	abstract[104]|abstract[106]|abstract[107]	new[104]|new[106]|new[107]	_	_
17-15	2047-2056	stability	abstract[104]|abstract[106]|abstract[107]|abstract	new[104]|new[106]|new[107]|new	_	_
17-16	2057-2058	,	_	_	_	_
17-17	2059-2066	causing	_	_	_	_
17-18	2067-2069	an	abstract[109]	new[109]	_	_
17-19	2070-2078	increase	abstract[109]	new[109]	_	_
17-20	2079-2081	in	abstract[109]	new[109]	_	_
17-21	2082-2091	residence	abstract[109]|place|time[111]	new[109]|new|new[111]	coref	17-28[113_111]
17-22	2092-2096	time	abstract[109]|time[111]	new[109]|new[111]	_	_
17-23	2097-2106	regarding	_	_	_	_
17-24	2107-2118	circulation	abstract	new	_	_
17-25	2119-2120	,	_	_	_	_
17-26	2121-2126	while	_	_	_	_
17-27	2127-2129	at	_	_	_	_
17-28	2130-2133	the	time[113]	giv[113]	_	_
17-29	2134-2138	same	time[113]	giv[113]	_	_
17-30	2139-2143	time	time[113]	giv[113]	_	_
17-31	2144-2151	causing	_	_	_	_
17-32	2152-2153	a	abstract[114]	new[114]	_	_
17-33	2154-2165	significant	abstract[114]	new[114]	_	_
17-34	2166-2174	decrease	abstract[114]	new[114]	_	_
17-35	2175-2177	in	abstract[114]	new[114]	_	_
17-36	2178-2186	toxicity	abstract[114]|abstract	new[114]|new	_	_
17-37	2187-2188	.	_	_	_	_

#Text=The encapsulation of bioactive ingredients within colloidal particles is an influential means of protecting them from degradation .
18-1	2189-2192	The	abstract[116]	new[116]	coref	18-10[120_116]
18-2	2193-2206	encapsulation	abstract[116]	new[116]	_	_
18-3	2207-2209	of	abstract[116]	new[116]	_	_
18-4	2210-2219	bioactive	abstract[116]|substance[117]	new[116]|new[117]	_	_
18-5	2220-2231	ingredients	abstract[116]|substance[117]	new[116]|new[117]	_	_
18-6	2232-2238	within	abstract[116]|substance[117]	new[116]|new[117]	_	_
18-7	2239-2248	colloidal	abstract[116]|substance[117]|object|object[119]	new[116]|new[117]|new|new[119]	ana	18-15[0_119]
18-8	2249-2258	particles	abstract[116]|substance[117]|object[119]	new[116]|new[117]|new[119]	_	_
18-9	2259-2261	is	_	_	_	_
18-10	2262-2264	an	abstract[120]	giv[120]	coref	29-15[0_120]
18-11	2265-2276	influential	abstract[120]	giv[120]	_	_
18-12	2277-2282	means	abstract[120]	giv[120]	_	_
18-13	2283-2285	of	_	_	_	_
18-14	2286-2296	protecting	_	_	_	_
18-15	2297-2301	them	object	giv	_	_
18-16	2302-2306	from	_	_	_	_
18-17	2307-2318	degradation	abstract	giv	ana	19-34
18-18	2319-2320	.	_	_	_	_

#Text=Different types of colloidal delivery systems have been developed , for example emulsions , nanoemulsions , microemulsions , liposomes , solid lipid nanoparticles , hydrogel beads , and biopolymer nanoparticles , each with its own advantages and disadvantages .
19-1	2321-2330	Different	abstract[123]	new[123]	_	_
19-2	2331-2336	types	abstract[123]	new[123]	_	_
19-3	2337-2339	of	abstract[123]	new[123]	_	_
19-4	2340-2349	colloidal	abstract[123]|abstract[125]	new[123]|new[125]	_	_
19-5	2350-2358	delivery	abstract[123]|abstract|abstract[125]	new[123]|giv|new[125]	coref	31-6
19-6	2359-2366	systems	abstract[123]|abstract[125]	new[123]|new[125]	_	_
19-7	2367-2371	have	_	_	_	_
19-8	2372-2376	been	_	_	_	_
19-9	2377-2386	developed	_	_	_	_
19-10	2387-2388	,	_	_	_	_
19-11	2389-2392	for	_	_	_	_
19-12	2393-2400	example	object[126]	new[126]	_	_
19-13	2401-2410	emulsions	object[126]	new[126]	_	_
19-14	2411-2412	,	_	_	_	_
19-15	2413-2426	nanoemulsions	object	new	_	_
19-16	2427-2428	,	_	_	_	_
19-17	2429-2443	microemulsions	object	new	_	_
19-18	2444-2445	,	_	_	_	_
19-19	2446-2455	liposomes	object	new	_	_
19-20	2456-2457	,	_	_	_	_
19-21	2458-2463	solid	object[131]	new[131]	_	_
19-22	2464-2469	lipid	person|object[131]	new|new[131]	_	_
19-23	2470-2483	nanoparticles	object[131]	new[131]	_	_
19-24	2484-2485	,	_	_	_	_
19-25	2486-2494	hydrogel	substance|object[133]	new|new[133]	_	_
19-26	2495-2500	beads	object[133]	new[133]	_	_
19-27	2501-2502	,	_	_	_	_
19-28	2503-2506	and	_	_	_	_
19-29	2507-2517	biopolymer	person|object[135]	new|new[135]	coref	36-12
19-30	2518-2531	nanoparticles	object[135]	new[135]	_	_
19-31	2532-2533	,	_	_	_	_
19-32	2534-2538	each	_	_	_	_
19-33	2539-2543	with	_	_	_	_
19-34	2544-2547	its	abstract|abstract[137]	giv|new[137]	_	_
19-35	2548-2551	own	abstract[137]	new[137]	_	_
19-36	2552-2562	advantages	abstract[137]	new[137]	_	_
19-37	2563-2566	and	_	_	_	_
19-38	2567-2580	disadvantages	abstract	new	_	_
19-39	2581-2582	.	_	_	_	_

#Text=Edible coating materials are usually composed of polysaccharides and proteins .
20-1	2583-2589	Edible	substance[140]	new[140]	coref	21-1[143_140]
20-2	2590-2597	coating	object|substance[140]	new|new[140]	_	_
20-3	2598-2607	materials	substance[140]	new[140]	_	_
20-4	2608-2611	are	_	_	_	_
20-5	2612-2619	usually	_	_	_	_
20-6	2620-2628	composed	_	_	_	_
20-7	2629-2631	of	_	_	_	_
20-8	2632-2647	polysaccharides	substance	new	coref	31-1
20-9	2648-2651	and	_	_	_	_
20-10	2652-2660	proteins	substance	giv	coref	34-9[248_0]
20-11	2661-2662	.	_	_	_	_

#Text=These materials could be used not only in the form of capsules , but also as films covering the food .
21-1	2663-2668	These	substance[143]	giv[143]	coref	35-13[257_143]
21-2	2669-2678	materials	substance[143]	giv[143]	_	_
21-3	2679-2684	could	_	_	_	_
21-4	2685-2687	be	_	_	_	_
21-5	2688-2692	used	_	_	_	_
21-6	2693-2696	not	_	_	_	_
21-7	2697-2701	only	abstract[144]	new[144]	_	_
21-8	2702-2704	in	abstract[144]	new[144]	_	_
21-9	2705-2708	the	abstract[144]	new[144]	_	_
21-10	2709-2713	form	abstract[144]	new[144]	_	_
21-11	2714-2716	of	abstract[144]	new[144]	_	_
21-12	2717-2725	capsules	abstract[144]|object	new[144]|new	_	_
21-13	2726-2727	,	_	_	_	_
21-14	2728-2731	but	_	_	_	_
21-15	2732-2736	also	_	_	_	_
21-16	2737-2739	as	_	_	_	_
21-17	2740-2745	films	object	new	coref	22-1[148_0]
21-18	2746-2754	covering	_	_	_	_
21-19	2755-2758	the	substance[147]	giv[147]	coref	22-10[0_147]
21-20	2759-2763	food	substance[147]	giv[147]	_	_
21-21	2764-2765	.	_	_	_	_

#Text=Edible films and coatings often containing bioactive agents or food additives like nutrients are gaining relevance as potential tools to reduce the deleterious effects of the incidence of microorganisms or to improve the nutritional value of a product .
22-1	2766-2772	Edible	object[148]	giv[148]	coref	23-9[163_148]
22-2	2773-2778	films	object[148]	giv[148]	_	_
22-3	2779-2782	and	object[148]	giv[148]	_	_
22-4	2783-2791	coatings	object[148]|object	giv[148]|new	_	_
22-5	2792-2797	often	_	_	_	_
22-6	2798-2808	containing	_	_	_	_
22-7	2809-2818	bioactive	substance[150]	new[150]	_	_
22-8	2819-2825	agents	substance[150]	new[150]	_	_
22-9	2826-2828	or	_	_	_	_
22-10	2829-2833	food	substance|substance[152]	giv|new[152]	coref	26-6
22-11	2834-2843	additives	substance[152]	new[152]	_	_
22-12	2844-2848	like	substance[152]	new[152]	_	_
22-13	2849-2858	nutrients	substance[152]|substance	new[152]|giv	_	_
22-14	2859-2862	are	_	_	_	_
22-15	2863-2870	gaining	_	_	_	_
22-16	2871-2880	relevance	abstract	new	_	_
22-17	2881-2883	as	_	_	_	_
22-18	2884-2893	potential	_	_	_	_
22-19	2894-2899	tools	_	_	_	_
22-20	2900-2902	to	_	_	_	_
22-21	2903-2909	reduce	_	_	_	_
22-22	2910-2913	the	abstract[155]	giv[155]	_	_
22-23	2914-2925	deleterious	abstract[155]	giv[155]	_	_
22-24	2926-2933	effects	abstract[155]	giv[155]	_	_
22-25	2934-2936	of	abstract[155]	giv[155]	_	_
22-26	2937-2940	the	abstract[155]|abstract[156]	giv[155]|new[156]	_	_
22-27	2941-2950	incidence	abstract[155]|abstract[156]	giv[155]|new[156]	_	_
22-28	2951-2953	of	abstract[155]|abstract[156]	giv[155]|new[156]	_	_
22-29	2954-2968	microorganisms	abstract[155]|abstract[156]|abstract	giv[155]|new[156]|new	_	_
22-30	2969-2971	or	_	_	_	_
22-31	2972-2974	to	_	_	_	_
22-32	2975-2982	improve	_	_	_	_
22-33	2983-2986	the	abstract[158]	new[158]	_	_
22-34	2987-2998	nutritional	abstract[158]	new[158]	_	_
22-35	2999-3004	value	abstract[158]	new[158]	_	_
22-36	3005-3007	of	abstract[158]	new[158]	_	_
22-37	3008-3009	a	abstract[158]|object[159]	new[158]|giv[159]	_	_
22-38	3010-3017	product	abstract[158]|object[159]	new[158]|giv[159]	_	_
22-39	3018-3019	.	_	_	_	_

#Text=In the research by Sapper et al. , polysaccharide protein films with the addition of thyme essential oil were obtained , which has a strong in vitro fungicidal effect .
23-1	3020-3022	In	_	_	_	_
23-2	3023-3026	the	abstract[160]	giv[160]	_	_
23-3	3027-3035	research	abstract[160]	giv[160]	_	_
23-4	3036-3038	by	abstract[160]	giv[160]	_	_
23-5	3039-3045	Sapper	abstract[160]|person	giv[160]|new	_	_
23-6	3046-3048	et	abstract[160]	giv[160]	_	_
23-7	3049-3052	al.	abstract[160]	giv[160]	_	_
23-8	3053-3054	,	_	_	_	_
23-9	3055-3069	polysaccharide	object[163]	giv[163]	coref	36-10[260_163]
23-10	3070-3077	protein	substance|object[163]	giv|giv[163]	coref	27-11
23-11	3078-3083	films	object[163]	giv[163]	_	_
23-12	3084-3088	with	object[163]	giv[163]	_	_
23-13	3089-3092	the	object[163]|abstract[164]	giv[163]|new[164]	_	_
23-14	3093-3101	addition	object[163]|abstract[164]	giv[163]|new[164]	_	_
23-15	3102-3104	of	object[163]|abstract[164]	giv[163]|new[164]	_	_
23-16	3105-3110	thyme	object[163]|abstract[164]|abstract|substance[166]	giv[163]|new[164]|new|new[166]	_	_
23-17	3111-3120	essential	object[163]|abstract[164]|substance[166]	giv[163]|new[164]|new[166]	_	_
23-18	3121-3124	oil	object[163]|abstract[164]|substance[166]	giv[163]|new[164]|new[166]	_	_
23-19	3125-3129	were	_	_	_	_
23-20	3130-3138	obtained	_	_	_	_
23-21	3139-3140	,	_	_	_	_
23-22	3141-3146	which	_	_	_	_
23-23	3147-3150	has	_	_	_	_
23-24	3151-3152	a	_	_	_	_
23-25	3153-3159	strong	_	_	_	_
23-26	3160-3162	in	_	_	_	_
23-27	3163-3168	vitro	abstract[167]	new[167]	coref	24-9[169_167]
23-28	3169-3179	fungicidal	abstract[167]	new[167]	_	_
23-29	3180-3186	effect	abstract[167]	new[167]	_	_
23-30	3187-3188	.	_	_	_	_

#Text=However , in vivo studies did not confirm the inhibitory effect on the surface of apples .
24-1	3189-3196	However	_	_	_	_
24-2	3197-3198	,	_	_	_	_
24-3	3199-3201	in	_	_	_	_
24-4	3202-3206	vivo	event[168]	new[168]	coref	28-1[186_168]
24-5	3207-3214	studies	event[168]	new[168]	_	_
24-6	3215-3218	did	_	_	_	_
24-7	3219-3222	not	_	_	_	_
24-8	3223-3230	confirm	_	_	_	_
24-9	3231-3234	the	abstract[169]	giv[169]	_	_
24-10	3235-3245	inhibitory	abstract[169]	giv[169]	_	_
24-11	3246-3252	effect	abstract[169]	giv[169]	_	_
24-12	3253-3255	on	abstract[169]	giv[169]	_	_
24-13	3256-3259	the	abstract[169]|place[170]	giv[169]|new[170]	_	_
24-14	3260-3267	surface	abstract[169]|place[170]	giv[169]|new[170]	_	_
24-15	3268-3270	of	abstract[169]|place[170]	giv[169]|new[170]	_	_
24-16	3271-3277	apples	abstract[169]|place[170]|plant	giv[169]|new[170]|new	_	_
24-17	3278-3279	.	_	_	_	_

#Text=Furthermore , other data from the literature indicate that the properties of biologically-active compounds tested in vitro are not always confirmed in vivo .
25-1	3280-3291	Furthermore	_	_	_	_
25-2	3292-3293	,	_	_	_	_
25-3	3294-3299	other	abstract[172]	new[172]	_	_
25-4	3300-3304	data	abstract[172]	new[172]	_	_
25-5	3305-3309	from	abstract[172]	new[172]	_	_
25-6	3310-3313	the	abstract[172]|abstract[173]	new[172]|new[173]	coref	29-8[196_173]
25-7	3314-3324	literature	abstract[172]|abstract[173]	new[172]|new[173]	_	_
25-8	3325-3333	indicate	_	_	_	_
25-9	3334-3338	that	_	_	_	_
25-10	3339-3342	the	abstract[174]	giv[174]	_	_
25-11	3343-3353	properties	abstract[174]	giv[174]	_	_
25-12	3354-3356	of	abstract[174]	giv[174]	_	_
25-13	3357-3376	biologically-active	abstract[174]|substance[175]	giv[174]|giv[175]	coref	26-5[179_175]
25-14	3377-3386	compounds	abstract[174]|substance[175]	giv[174]|giv[175]	_	_
25-15	3387-3393	tested	_	_	_	_
25-16	3394-3396	in	_	_	_	_
25-17	3397-3402	vitro	_	_	_	_
25-18	3403-3406	are	_	_	_	_
25-19	3407-3410	not	_	_	_	_
25-20	3411-3417	always	_	_	_	_
25-21	3418-3427	confirmed	_	_	_	_
25-22	3428-3430	in	_	_	_	_
25-23	3431-3435	vivo	_	_	_	_
25-24	3436-3437	.	_	_	_	_

#Text=Bioactive peptides differ from other food bioactive compounds like vitamins or polyphenols .
26-1	3438-3447	Bioactive	abstract|object[177]	new|giv[177]	coref	28-4[187_177]
26-2	3448-3456	peptides	object[177]	giv[177]	_	_
26-3	3457-3463	differ	_	_	_	_
26-4	3464-3468	from	_	_	_	_
26-5	3469-3474	other	substance[179]	giv[179]	_	_
26-6	3475-3479	food	substance|substance[179]	giv|giv[179]	coref	33-43
26-7	3480-3489	bioactive	substance[179]	giv[179]	_	_
26-8	3490-3499	compounds	substance[179]	giv[179]	_	_
26-9	3500-3504	like	substance[179]	giv[179]	_	_
26-10	3505-3513	vitamins	substance[179]|substance	giv[179]|new	_	_
26-11	3514-3516	or	substance[179]	giv[179]	_	_
26-12	3517-3528	polyphenols	substance[179]|substance	giv[179]|new	_	_
26-13	3529-3530	.	_	_	_	_

#Text=There is slight heterogeneity regarding the chemical species in the protein hydrolysates .
27-1	3531-3536	There	_	_	_	_
27-2	3537-3539	is	_	_	_	_
27-3	3540-3546	slight	abstract[182]	new[182]	_	_
27-4	3547-3560	heterogeneity	abstract[182]	new[182]	_	_
27-5	3561-3570	regarding	_	_	_	_
27-6	3571-3574	the	abstract[183]	giv[183]	_	_
27-7	3575-3583	chemical	abstract[183]	giv[183]	_	_
27-8	3584-3591	species	abstract[183]	giv[183]	_	_
27-9	3592-3594	in	abstract[183]	giv[183]	_	_
27-10	3595-3598	the	abstract[183]|abstract[185]	giv[183]|giv[185]	_	_
27-11	3599-3606	protein	abstract[183]|substance|abstract[185]	giv[183]|giv|giv[185]	coref	28-12
27-12	3607-3619	hydrolysates	abstract[183]|abstract[185]	giv[183]|giv[185]	_	_
27-13	3620-3621	.	_	_	_	_

#Text=Most studies on bioactive peptides focus on finding new bioactivity and protein precursors , while limited attention is paid to their biostability or bioavailability .
28-1	3622-3626	Most	event[186]	giv[186]	coref	30-9[202_186]
28-2	3627-3634	studies	event[186]	giv[186]	_	_
28-3	3635-3637	on	event[186]	giv[186]	_	_
28-4	3638-3647	bioactive	event[186]|object[187]	giv[186]|giv[187]	coref	29-17[199_187]
28-5	3648-3656	peptides	event[186]|object[187]	giv[186]|giv[187]	_	_
28-6	3657-3662	focus	_	_	_	_
28-7	3663-3665	on	_	_	_	_
28-8	3666-3673	finding	_	_	_	_
28-9	3674-3677	new	abstract[188]	new[188]	coref	30-21[0_188]
28-10	3678-3689	bioactivity	abstract[188]	new[188]	_	_
28-11	3690-3693	and	_	_	_	_
28-12	3694-3701	protein	substance|substance[190]	giv|new[190]	ana	28-21[0_190]
28-13	3702-3712	precursors	substance[190]	new[190]	_	_
28-14	3713-3714	,	_	_	_	_
28-15	3715-3720	while	_	_	_	_
28-16	3721-3728	limited	abstract[191]	new[191]	_	_
28-17	3729-3738	attention	abstract[191]	new[191]	_	_
28-18	3739-3741	is	_	_	_	_
28-19	3742-3746	paid	_	_	_	_
28-20	3747-3749	to	_	_	_	_
28-21	3750-3755	their	substance|abstract[193]	giv|new[193]	_	_
28-22	3756-3768	biostability	abstract[193]	new[193]	_	_
28-23	3769-3771	or	_	_	_	_
28-24	3772-3787	bioavailability	substance	new	_	_
28-25	3788-3789	.	_	_	_	_

#Text=Presently , there is a gap in the literature illustrating the various aspects of encapsulation concerning food-protein-derived bioactive peptides .
29-1	3790-3799	Presently	_	_	_	_
29-2	3800-3801	,	_	_	_	_
29-3	3802-3807	there	_	_	_	_
29-4	3808-3810	is	_	_	_	_
29-5	3811-3812	a	abstract[195]	new[195]	_	_
29-6	3813-3816	gap	abstract[195]	new[195]	_	_
29-7	3817-3819	in	abstract[195]	new[195]	_	_
29-8	3820-3823	the	abstract[195]|abstract[196]	new[195]|giv[196]	_	_
29-9	3824-3834	literature	abstract[195]|abstract[196]	new[195]|giv[196]	_	_
29-10	3835-3847	illustrating	_	_	_	_
29-11	3848-3851	the	abstract[197]	new[197]	_	_
29-12	3852-3859	various	abstract[197]	new[197]	_	_
29-13	3860-3867	aspects	abstract[197]	new[197]	_	_
29-14	3868-3870	of	abstract[197]	new[197]	_	_
29-15	3871-3884	encapsulation	abstract[197]|abstract	new[197]|giv	coref	30-19[206_0]
29-16	3885-3895	concerning	_	_	_	_
29-17	3896-3916	food-protein-derived	object[199]	giv[199]	_	_
29-18	3917-3926	bioactive	object[199]	giv[199]	_	_
29-19	3927-3935	peptides	object[199]	giv[199]	_	_
29-20	3936-3937	.	_	_	_	_

#Text=Moreover , there is a need for in vivo studies applying animal models to confirm the success of encapsulation in bioactivity retention following the oral consumption of these products .
30-1	3938-3946	Moreover	_	_	_	_
30-2	3947-3948	,	_	_	_	_
30-3	3949-3954	there	_	_	_	_
30-4	3955-3957	is	_	_	_	_
30-5	3958-3959	a	abstract[200]	new[200]	_	_
30-6	3960-3964	need	abstract[200]	new[200]	_	_
30-7	3965-3968	for	abstract[200]	new[200]	_	_
30-8	3969-3971	in	abstract[200]	new[200]	_	_
30-9	3972-3976	vivo	abstract[200]|abstract|event[202]	new[200]|new|giv[202]	_	_
30-10	3977-3984	studies	abstract[200]|event[202]	new[200]|giv[202]	_	_
30-11	3985-3993	applying	_	_	_	_
30-12	3994-4000	animal	person|abstract[204]	new|new[204]	ana	31-11[0_204]
30-13	4001-4007	models	abstract[204]	new[204]	_	_
30-14	4008-4010	to	_	_	_	_
30-15	4011-4018	confirm	_	_	_	_
30-16	4019-4022	the	abstract[205]	new[205]	_	_
30-17	4023-4030	success	abstract[205]	new[205]	_	_
30-18	4031-4033	of	abstract[205]	new[205]	_	_
30-19	4034-4047	encapsulation	abstract[205]|abstract[206]	new[205]|giv[206]	coref	34-17[249_206]
30-20	4048-4050	in	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
30-21	4051-4062	bioactivity	abstract[205]|abstract[206]|abstract|abstract[208]	new[205]|giv[206]|giv|new[208]	_	_
30-22	4063-4072	retention	abstract[205]|abstract[206]|abstract[208]	new[205]|giv[206]|new[208]	_	_
30-23	4073-4082	following	_	_	_	_
30-24	4083-4086	the	abstract[209]	new[209]	_	_
30-25	4087-4091	oral	abstract[209]	new[209]	_	_
30-26	4092-4103	consumption	abstract[209]	new[209]	_	_
30-27	4104-4106	of	abstract[209]	new[209]	_	_
30-28	4107-4112	these	abstract[209]|substance[210]	new[209]|new[210]	_	_
30-29	4113-4121	products	abstract[209]|substance[210]	new[209]|new[210]	_	_
30-30	4122-4123	.	_	_	_	_

#Text=Polysaccharides are generally ideal as delivery agents in microcapsules as they are structurally stable , ample in nature , and inexpensive .
31-1	4124-4139	Polysaccharides	object	giv	coref	32-1[216_0]
31-2	4140-4143	are	_	_	_	_
31-3	4144-4153	generally	_	_	_	_
31-4	4154-4159	ideal	_	_	_	_
31-5	4160-4162	as	_	_	_	_
31-6	4163-4171	delivery	abstract	giv	_	_
31-7	4172-4178	agents	_	_	_	_
31-8	4179-4181	in	_	_	_	_
31-9	4182-4195	microcapsules	object	new	_	_
31-10	4196-4198	as	_	_	_	_
31-11	4199-4203	they	abstract	giv	_	_
31-12	4204-4207	are	_	_	_	_
31-13	4208-4220	structurally	_	_	_	_
31-14	4221-4227	stable	_	_	_	_
31-15	4228-4229	,	_	_	_	_
31-16	4230-4235	ample	_	_	_	_
31-17	4236-4238	in	_	_	_	_
31-18	4239-4245	nature	abstract	new	_	_
31-19	4246-4247	,	_	_	_	_
31-20	4248-4251	and	_	_	_	_
31-21	4252-4263	inexpensive	_	_	_	_
31-22	4264-4265	.	_	_	_	_

#Text=Polysaccharides with reactive functional groups ( carboxyl ( COOH ) ) , hydroxyl ( OH ) , amide ( NH2 ) , and sulphate groups ( SO4H ) ) are good candidates as carrier matrices . Furcellaran ( FUR ) is structurally connected with the algal polysaccharide κ carrageenan ; however , there is a major structural difference .
32-1	4266-4281	Polysaccharides	person[216]	giv[216]	coref	32-31[225_216]
32-2	4282-4286	with	person[216]	giv[216]	_	_
32-3	4287-4295	reactive	person[216]|person[217]	giv[216]|new[217]	_	_
32-4	4296-4306	functional	person[216]|person[217]	giv[216]|new[217]	_	_
32-5	4307-4313	groups	person[216]|person[217]	giv[216]|new[217]	_	_
32-6	4314-4315	(	_	_	_	_
32-7	4316-4324	carboxyl	substance	new	_	_
32-8	4325-4326	(	_	_	_	_
32-9	4327-4331	COOH	abstract	new	_	_
32-10	4332-4333	)	_	_	_	_
32-11	4334-4335	)	_	_	_	_
32-12	4336-4337	,	_	_	_	_
32-13	4338-4346	hydroxyl	abstract	new	_	_
32-14	4347-4348	(	_	_	_	_
32-15	4349-4351	OH	_	_	_	_
32-16	4352-4353	)	_	_	_	_
32-17	4354-4355	,	_	_	_	_
32-18	4356-4361	amide	abstract	new	appos	32-20
32-19	4362-4363	(	_	_	_	_
32-20	4364-4367	NH2	abstract	giv	_	_
32-21	4368-4369	)	_	_	_	_
32-22	4370-4371	,	_	_	_	_
32-23	4372-4375	and	_	_	_	_
32-24	4376-4384	sulphate	person[223]	new[223]	_	_
32-25	4385-4391	groups	person[223]	new[223]	_	_
32-26	4392-4393	(	_	_	_	_
32-27	4394-4398	SO4H	substance	new	_	_
32-28	4399-4400	)	_	_	_	_
32-29	4401-4402	)	_	_	_	_
32-30	4403-4406	are	_	_	_	_
32-31	4407-4411	good	person[225]	giv[225]	coref	35-6[0_225]
32-32	4412-4422	candidates	person[225]	giv[225]	_	_
32-33	4423-4425	as	person[225]	giv[225]	_	_
32-34	4426-4433	carrier	person[225]	giv[225]	_	_
32-35	4434-4442	matrices	person[225]	giv[225]	_	_
32-36	4443-4444	.	_	_	_	_
32-37	4445-4456	Furcellaran	substance	new	coref	33-1
32-38	4457-4458	(	_	_	_	_
32-39	4459-4462	FUR	object	new	_	_
32-40	4463-4464	)	_	_	_	_
32-41	4465-4467	is	_	_	_	_
32-42	4468-4480	structurally	_	_	_	_
32-43	4481-4490	connected	_	_	_	_
32-44	4491-4495	with	_	_	_	_
32-45	4496-4499	the	abstract[230]	new[230]	_	_
32-46	4500-4505	algal	abstract[230]	new[230]	_	_
32-47	4506-4520	polysaccharide	substance|abstract[230]	new|new[230]	_	_
32-48	4521-4522	κ	abstract|abstract[230]	new|new[230]	_	_
32-49	4523-4534	carrageenan	abstract[230]	new[230]	_	_
32-50	4535-4536	;	_	_	_	_
32-51	4537-4544	however	_	_	_	_
32-52	4545-4546	,	_	_	_	_
32-53	4547-4552	there	_	_	_	_
32-54	4553-4555	is	_	_	_	_
32-55	4556-4557	a	abstract[231]	new[231]	_	_
32-56	4558-4563	major	abstract[231]	new[231]	_	_
32-57	4564-4574	structural	abstract[231]	new[231]	_	_
32-58	4575-4585	difference	abstract[231]	new[231]	_	_
32-59	4586-4587	.	_	_	_	_

#Text=Furcellaran , which has units consisting of a fragment of ( 1 – 3 ) β-D-galactopyranose with a sulphate group at C-4 and ( 1 – 4 ) -3 , 6-anhydro-α-D-galactopyranose , is used as a gelling and stabilizing agent in the food industry .
33-1	4588-4599	Furcellaran	substance	giv	coref	34-4
33-2	4600-4601	,	_	_	_	_
33-3	4602-4607	which	_	_	_	_
33-4	4608-4611	has	_	_	_	_
33-5	4612-4617	units	object	new	_	_
33-6	4618-4628	consisting	_	_	_	_
33-7	4629-4631	of	_	_	_	_
33-8	4632-4633	a	abstract[234]	new[234]	_	_
33-9	4634-4642	fragment	abstract[234]	new[234]	_	_
33-10	4643-4645	of	_	_	_	_
33-11	4646-4647	(	_	_	_	_
33-12	4648-4649	1	time[235]	new[235]	_	_
33-13	4650-4651	–	time[235]	new[235]	_	_
33-14	4652-4653	3	time[235]|quantity	new[235]|new	_	_
33-15	4654-4655	)	_	_	_	_
33-16	4656-4675	β-D-galactopyranose	substance[237]	new[237]	_	_
33-17	4676-4680	with	substance[237]	new[237]	_	_
33-18	4681-4682	a	substance[237]|person[239]	new[237]|new[239]	_	_
33-19	4683-4691	sulphate	substance[237]|abstract|person[239]	new[237]|new|new[239]	_	_
33-20	4692-4697	group	substance[237]|person[239]	new[237]|new[239]	_	_
33-21	4698-4700	at	substance[237]|person[239]	new[237]|new[239]	_	_
33-22	4701-4704	C-4	substance[237]|person[239]|abstract	new[237]|new[239]|new	_	_
33-23	4705-4708	and	substance[237]|person[239]	new[237]|new[239]	_	_
33-24	4709-4710	(	substance[237]|person[239]	new[237]|new[239]	_	_
33-25	4711-4712	1	substance[237]|person[239]	new[237]|new[239]	_	_
33-26	4713-4714	–	substance[237]|person[239]	new[237]|new[239]	_	_
33-27	4715-4716	4	substance[237]|person[239]|quantity	new[237]|new[239]|new	_	_
33-28	4717-4718	)	substance[237]|person[239]	new[237]|new[239]	_	_
33-29	4719-4721	-3	substance[237]|person[239]|abstract[242]	new[237]|new[239]|new[242]	_	_
33-30	4722-4723	,	substance[237]|person[239]|abstract[242]	new[237]|new[239]|new[242]	_	_
33-31	4724-4753	6-anhydro-α-D-galactopyranose	substance[237]|person[239]|abstract[242]|animal	new[237]|new[239]|new[242]|new	_	_
33-32	4754-4755	,	_	_	_	_
33-33	4756-4758	is	_	_	_	_
33-34	4759-4763	used	_	_	_	_
33-35	4764-4766	as	_	_	_	_
33-36	4767-4768	a	_	_	_	_
33-37	4769-4776	gelling	_	_	_	_
33-38	4777-4780	and	_	_	_	_
33-39	4781-4792	stabilizing	_	_	_	_
33-40	4793-4798	agent	_	_	_	_
33-41	4799-4801	in	_	_	_	_
33-42	4802-4805	the	abstract[245]	giv[245]	_	_
33-43	4806-4810	food	substance|abstract[245]	giv|giv[245]	coref	34-19
33-44	4811-4819	industry	abstract[245]	giv[245]	_	_
33-45	4820-4821	.	_	_	_	_

#Text=In addition , furcellaran can form complexes with various proteins , which can be used for encapsulation in food and agriculture applications .
34-1	4822-4824	In	_	_	_	_
34-2	4825-4833	addition	_	_	_	_
34-3	4834-4835	,	_	_	_	_
34-4	4836-4847	furcellaran	substance	giv	coref	36-1[258_0]
34-5	4848-4851	can	_	_	_	_
34-6	4852-4856	form	_	_	_	_
34-7	4857-4866	complexes	substance[247]	new[247]	_	_
34-8	4867-4871	with	substance[247]	new[247]	_	_
34-9	4872-4879	various	substance[247]|substance[248]	new[247]|giv[248]	coref	35-4[254_248]
34-10	4880-4888	proteins	substance[247]|substance[248]	new[247]|giv[248]	_	_
34-11	4889-4890	,	_	_	_	_
34-12	4891-4896	which	_	_	_	_
34-13	4897-4900	can	_	_	_	_
34-14	4901-4903	be	_	_	_	_
34-15	4904-4908	used	_	_	_	_
34-16	4909-4912	for	_	_	_	_
34-17	4913-4926	encapsulation	abstract[249]	giv[249]	coref	36-21[0_249]
34-18	4927-4929	in	abstract[249]	giv[249]	_	_
34-19	4930-4934	food	abstract[249]|substance|abstract[252]	giv[249]|giv|new[252]	_	_
34-20	4935-4938	and	abstract[249]|abstract[252]	giv[249]|new[252]	_	_
34-21	4939-4950	agriculture	abstract[249]|abstract|abstract[252]	giv[249]|new|new[252]	_	_
34-22	4951-4963	applications	abstract[249]|abstract[252]	giv[249]|new[252]	_	_
34-23	4964-4965	.	_	_	_	_

#Text=The interactions between proteins and polysaccharides can lead to the creation of completely new materials .
35-1	4966-4969	The	abstract[253]	giv[253]	_	_
35-2	4970-4982	interactions	abstract[253]	giv[253]	_	_
35-3	4983-4990	between	abstract[253]	giv[253]	_	_
35-4	4991-4999	proteins	abstract[253]|substance[254]	giv[253]|giv[254]	_	_
35-5	5000-5003	and	abstract[253]|substance[254]	giv[253]|giv[254]	_	_
35-6	5004-5019	polysaccharides	abstract[253]|substance[254]|substance	giv[253]|giv[254]|giv	_	_
35-7	5020-5023	can	_	_	_	_
35-8	5024-5028	lead	_	_	_	_
35-9	5029-5031	to	_	_	_	_
35-10	5032-5035	the	event[256]	new[256]	_	_
35-11	5036-5044	creation	event[256]	new[256]	_	_
35-12	5045-5047	of	event[256]	new[256]	_	_
35-13	5048-5058	completely	event[256]|substance[257]	new[256]|giv[257]	_	_
35-14	5059-5062	new	event[256]|substance[257]	new[256]|giv[257]	_	_
35-15	5063-5072	materials	event[256]|substance[257]	new[256]|giv[257]	_	_
35-16	5073-5074	.	_	_	_	_

#Text=Negatively-charged furcellaran can act as a film-forming matrix in active , biopolymer films and as a carrier material in the encapsulation process .
36-1	5075-5093	Negatively-charged	substance[258]	giv[258]	_	_
36-2	5094-5105	furcellaran	substance[258]	giv[258]	_	_
36-3	5106-5109	can	_	_	_	_
36-4	5110-5113	act	_	_	_	_
36-5	5114-5116	as	_	_	_	_
36-6	5117-5118	a	_	_	_	_
36-7	5119-5131	film-forming	_	_	_	_
36-8	5132-5138	matrix	_	_	_	_
36-9	5139-5141	in	_	_	_	_
36-10	5142-5148	active	object[260]	giv[260]	_	_
36-11	5149-5150	,	object[260]	giv[260]	_	_
36-12	5151-5161	biopolymer	person|object[260]	giv|giv[260]	_	_
36-13	5162-5167	films	object[260]	giv[260]	_	_
36-14	5168-5171	and	_	_	_	_
36-15	5172-5174	as	_	_	_	_
36-16	5175-5176	a	_	_	_	_
36-17	5177-5184	carrier	_	_	_	_
36-18	5185-5193	material	_	_	_	_
36-19	5194-5196	in	_	_	_	_
36-20	5197-5200	the	event[262]	new[262]	_	_
36-21	5201-5214	encapsulation	abstract|event[262]	giv|new[262]	_	_
36-22	5215-5222	process	event[262]	new[262]	_	_
36-23	5223-5224	.	_	_	_	_
